Mor­phoSys swoops in with a $1.7B deal to buy Con­stel­la­tion, adds $2B-plus in Roy­al­ty pact

Ger­many’s Mor­phoSys has swooped in to buy can­cer drug de­vel­op­er Con­stel­la­tion $CNST in a deal that val­ues the com­pa­ny at $1.7 bil­lion. And they’re fund­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.